A Phase II Randomized, Placebo Controlled, Double-blind, Four Arms Dose-ranging Study to Evaluate the Efficacy and Safety of SHR0302 Compared to Placebo in Patients With Moderate to Severe Active Crohn's Disease
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs SHR 0302 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Reistone Biopharma
- 15 Aug 2019 Status changed from active, no longer recruiting to recruiting.
- 14 Jun 2019 According to a Reistone Biopharma media release, first patient has been dosed in this study.
- 21 May 2019 Status changed from recruiting to active, no longer recruiting.